Overview

Atoguanil BA Study

Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This trial aims to characterise the pharmacokinetic (PK) profile and estimate drug exposure from Atoguanil in comparison to Malarone®.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborator:
Richmond Pharmacology Limited
Treatments:
Atovaquone, proguanil drug combination